Covieshield Court rejects Cutis Biotech's move to restrict Serum Institute from using Covishield trademark
Pune/IBNS: A civil court in Pune rejected drug company Cutis Biotech's move to stop the Serum Institute of India (SII) from using the trademark "Covishield", media reports said.
Earlier in the month, Cutis Biotech had filed a suit in the civil court seeking to restrain Adar Poonawalla's Serum Institute from using the trademark "Covishield" or other similar names for its COVID-19 vaccine.
The Maharashtra-based pharmaceutical company, Cutis Biotech, had claimed to be using the brand name "Covishield" before the Serum Institute did.
In its response, the Serum Institute said both companies operate in different product categories and there is no scope for confusion over the trademark, the lawyers representing the world's largest maker of vaccines said.
Following the reply, the civil court in Pune then rejected the injunction application filed on behalf of Cutis Biotech against the Serum Institute, the lawyers told media.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
